➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
McKesson
Colorcon
Medtronic
Merck
Moodys

Last Updated: August 7, 2020

DrugPatentWatch Database Preview

Eculizumab - Biologic Drug Details

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Recent Clinical Trials for eculizumab

Identify potential brand extensions & biosimilar entrants

SponsorPhase
Hoffmann-La RochePhase 3
Chugai PharmaceuticalPhase 3
Assistance Publique - Hôpitaux de ParisPhase 2

See all eculizumab clinical trials

Recent Litigation for eculizumab

Identify key patents and potential future biosimilar entrants

PTAB Litigation
PetitionerDate
Amgen Inc.2019-02-28
Amgen, Inc.2019-02-28
2017-12-20

See all eculizumab litigation

Pharmacology for eculizumab
Mechanism of ActionComplement Inhibitors

Company Disclosures: US Patents for eculizumab

These patents were extracted from company disclosures
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Alexion Pharm SOLIRIS eculizumab INJECTABLE; IV (INFUSION) 125166 001 2007-03-16   Start Trial Alexion Pharmaceuticals, Inc. (Cheshire, CT) 2019-03-12 RX Orphan company
Alexion Pharm SOLIRIS eculizumab INJECTABLE; IV (INFUSION) 125166 001 2007-03-16   Start Trial Alexion Pharmaceuticals, Inc. (New Haven, CT) 2027-03-15 RX Orphan company
Alexion Pharm SOLIRIS eculizumab INJECTABLE; IV (INFUSION) 125166 001 2007-03-16   Start Trial Alexion Pharmaceuticals, Inc. (New Haven, CT) 2027-03-15 RX Orphan company
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Patent Text Search: US Patents for eculizumab

These patents were identified by searching patent claims

Supplementary Protection Certificates for eculizumab

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0758904/01 Switzerland   Start Trial FORMER REPRESENTATIVE: VOSSIUS AND PARTNER, CH
2009000075 Germany   Start Trial PRODUCT NAME: ECULIZUMAB; REGISTRATION NO/DATE: EU/1/07/393/001 20070620
12/2010 Austria   Start Trial PRODUCT NAME: ECULIZUMAB
2010901820871 Italy   Start Trial PRODUCT NAME: ECULIZUMAB(SOLIRIS); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/07/393/001, 20070620
C/GB10/015 United Kingdom   Start Trial PRODUCT NAME: ECULIZUMAB; REGISTERED: UK EU/1/07/393/001 20070620
C002/2010 Ireland   Start Trial SPC002/2010: 20100902, EXPIRES: 20200430
C0016 France   Start Trial PRODUCT NAME: ECULIZUMAB; REGISTRATION NO/DATE: EU/1/07/393/001 20070620
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Medtronic
Harvard Business School
McKinsey
Moodys
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.